AGP Executive Report
Last update: 5 hours agoBladder Cancer Drug Approval: Merck’s KEYTRUDA (pembrolizumab) plus PADCEV (enfortumab vedotin) won a positive CHMP opinion for perioperative treatment of resectable muscle-invasive bladder cancer, with a European Commission decision expected in Q4 2026; the recommendation also covers a subcutaneous KEYTRUDA formulation for EU, Iceland, Liechtenstein and Norway. EU–Canada Industrial Partnership: Ursula von der Leyen floated Canada as the EU’s first “associate member,” but the term has no clear treaty basis yet—talks point to deeper cooperation in intelligent manufacturing, tech, defence industry integration, energy, critical minerals and the Arctic, with Canada stressing it is not seeking full membership. Solar Supply Chain Costs: The US Section 232 action sets new minimum import prices and a 15% tariff on certain polysilicon derivatives, with Liechtenstein and Switzerland facing capped tariff treatment—raising the stakes for European solar equipment pricing from Dec 2026. Space Research Access: The Center for Space and Aviation Switzerland and Liechtenstein is building a pathway to move experiments from ground testing to the ISS via Starlab and ISS access opportunities, linking Dübendorf and Zurich innovation infrastructure. Digital Banking in Liechtenstein’s Region: Crédit Agricole next bank went live in Switzerland with Avaloq’s new mobile banking app, using a SaaS model to expand payment and investment self-service—relevant for regional fintech and regulated finance operators.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
![<![CDATA[Pembrolizumab/Enfortumab Vedotin Earns Positive CHMP Opinion in MIBC]]>](https://2c717466dc25cd7041c9-8eeda6a8ca964cf210ed223dbc947813.ssl.cf2.rackcdn.com/27123886-930626510-5eb41dddc2582afbc99f50c263359de127e4fa9c-5500x4000-100x73.jpeg)
![<![CDATA[Pembrolizumab/Enfortumab Vedotin Earns Positive CHMP Opinion in MIBC]]>](/images/news-fallback.svg)
